nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—PSMB8—parotid gland—pharynx cancer	0.0361	0.061	CbGeAlD
Carfilzomib—PSMB10—lymphoid tissue—pharynx cancer	0.036	0.0609	CbGeAlD
Carfilzomib—PSMB8—saliva-secreting gland—pharynx cancer	0.0345	0.0584	CbGeAlD
Carfilzomib—PSMB5—parotid gland—pharynx cancer	0.0318	0.0539	CbGeAlD
Carfilzomib—PSMB5—saliva-secreting gland—pharynx cancer	0.0305	0.0516	CbGeAlD
Carfilzomib—PSMB10—head—pharynx cancer	0.029	0.0491	CbGeAlD
Carfilzomib—PSMB1—parotid gland—pharynx cancer	0.0278	0.0471	CbGeAlD
Carfilzomib—PSMB2—parotid gland—pharynx cancer	0.0272	0.0459	CbGeAlD
Carfilzomib—PSMB1—saliva-secreting gland—pharynx cancer	0.0267	0.0451	CbGeAlD
Carfilzomib—PSMB8—trachea—pharynx cancer	0.0266	0.0451	CbGeAlD
Carfilzomib—PSMB2—saliva-secreting gland—pharynx cancer	0.026	0.044	CbGeAlD
Carfilzomib—PSMB5—trachea—pharynx cancer	0.0235	0.0398	CbGeAlD
Carfilzomib—PSMB1—trachea—pharynx cancer	0.0206	0.0348	CbGeAlD
Carfilzomib—PSMB10—lymph node—pharynx cancer	0.0203	0.0344	CbGeAlD
Carfilzomib—PSMB2—trachea—pharynx cancer	0.0201	0.0339	CbGeAlD
Carfilzomib—PSMB5—spinal cord—pharynx cancer	0.0186	0.0314	CbGeAlD
Carfilzomib—PSMB1—lymphoid tissue—pharynx cancer	0.0179	0.0303	CbGeAlD
Carfilzomib—PSMB2—lymphoid tissue—pharynx cancer	0.0175	0.0296	CbGeAlD
Carfilzomib—PSMB1—spinal cord—pharynx cancer	0.0162	0.0275	CbGeAlD
Carfilzomib—PSMB2—spinal cord—pharynx cancer	0.0158	0.0268	CbGeAlD
Carfilzomib—PSMB1—head—pharynx cancer	0.0144	0.0244	CbGeAlD
Carfilzomib—PSMB2—head—pharynx cancer	0.0141	0.0238	CbGeAlD
Carfilzomib—PSMB10—Amino acid and derivative metabolism—CNDP2—pharynx cancer	0.0134	0.0327	CbGpPWpGaD
Carfilzomib—PSMB9—Amino acid and derivative metabolism—CNDP2—pharynx cancer	0.0133	0.0325	CbGpPWpGaD
Carfilzomib—PSMB8—lymph node—pharynx cancer	0.0131	0.0221	CbGeAlD
Carfilzomib—PSMB5—lymph node—pharynx cancer	0.0116	0.0196	CbGeAlD
Carfilzomib—PSMB5—Amino acid and derivative metabolism—CNDP2—pharynx cancer	0.0101	0.0248	CbGpPWpGaD
Carfilzomib—PSMB1—Amino acid and derivative metabolism—CNDP2—pharynx cancer	0.0101	0.0248	CbGpPWpGaD
Carfilzomib—PSMB2—Amino acid and derivative metabolism—CNDP2—pharynx cancer	0.0101	0.0248	CbGpPWpGaD
Carfilzomib—PSMB1—lymph node—pharynx cancer	0.0101	0.0171	CbGeAlD
Carfilzomib—PSMB8—Amino acid and derivative metabolism—CNDP2—pharynx cancer	0.00999	0.0244	CbGpPWpGaD
Carfilzomib—PSMB2—lymph node—pharynx cancer	0.00986	0.0167	CbGeAlD
Carfilzomib—PSMB10—Ubiquitin-dependent degradation of Cyclin D—CCND1—pharynx cancer	0.00676	0.0165	CbGpPWpGaD
Carfilzomib—PSMB9—Ubiquitin-dependent degradation of Cyclin D—CCND1—pharynx cancer	0.00672	0.0164	CbGpPWpGaD
Carfilzomib—PSMB10—B Cell Activation—CD79A—pharynx cancer	0.00539	0.0132	CbGpPWpGaD
Carfilzomib—PSMB9—B Cell Activation—CD79A—pharynx cancer	0.00536	0.0131	CbGpPWpGaD
Carfilzomib—PSMB2—Ubiquitin-dependent degradation of Cyclin D—CCND1—pharynx cancer	0.00512	0.0125	CbGpPWpGaD
Carfilzomib—PSMB1—Ubiquitin-dependent degradation of Cyclin D—CCND1—pharynx cancer	0.00512	0.0125	CbGpPWpGaD
Carfilzomib—PSMB5—Ubiquitin-dependent degradation of Cyclin D—CCND1—pharynx cancer	0.00512	0.0125	CbGpPWpGaD
Carfilzomib—PSMB8—Ubiquitin-dependent degradation of Cyclin D—CCND1—pharynx cancer	0.00505	0.0123	CbGpPWpGaD
Carfilzomib—PSMB10—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00438	0.0107	CbGpPWpGaD
Carfilzomib—PSMB9—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00436	0.0107	CbGpPWpGaD
Carfilzomib—PSMB10—Stabilization of p53—TP53—pharynx cancer	0.00431	0.0105	CbGpPWpGaD
Carfilzomib—PSMB9—Stabilization of p53—TP53—pharynx cancer	0.00429	0.0105	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—CD79A—pharynx cancer	0.00408	0.00999	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—CD79A—pharynx cancer	0.00408	0.00999	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—CD79A—pharynx cancer	0.00408	0.00999	CbGpPWpGaD
Carfilzomib—PSMB8—B Cell Activation—CD79A—pharynx cancer	0.00403	0.00985	CbGpPWpGaD
Carfilzomib—PSMB10—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.004	0.00978	CbGpPWpGaD
Carfilzomib—PSMB9—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.00398	0.00974	CbGpPWpGaD
Carfilzomib—PSMB10—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00384	0.00938	CbGpPWpGaD
Carfilzomib—PSMB9—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00382	0.00934	CbGpPWpGaD
Carfilzomib—PSMB10—Apoptosis—CDH1—pharynx cancer	0.00361	0.00882	CbGpPWpGaD
Carfilzomib—PSMB9—Apoptosis—CDH1—pharynx cancer	0.00359	0.00878	CbGpPWpGaD
Carfilzomib—ABCB1—epithelium—pharynx cancer	0.00347	0.00586	CbGeAlD
Carfilzomib—PSMB5—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00332	0.00812	CbGpPWpGaD
Carfilzomib—PSMB1—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00332	0.00812	CbGpPWpGaD
Carfilzomib—PSMB2—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00332	0.00812	CbGpPWpGaD
Carfilzomib—PSMB8—Autodegradation of the E3 ubiquitin ligase COP1—TP53—pharynx cancer	0.00327	0.008	CbGpPWpGaD
Carfilzomib—PSMB5—Stabilization of p53—TP53—pharynx cancer	0.00327	0.00799	CbGpPWpGaD
Carfilzomib—PSMB1—Stabilization of p53—TP53—pharynx cancer	0.00327	0.00799	CbGpPWpGaD
Carfilzomib—PSMB2—Stabilization of p53—TP53—pharynx cancer	0.00327	0.00799	CbGpPWpGaD
Carfilzomib—PSMB10—S Phase—CCND1—pharynx cancer	0.00324	0.00791	CbGpPWpGaD
Carfilzomib—PSMB8—Stabilization of p53—TP53—pharynx cancer	0.00322	0.00788	CbGpPWpGaD
Carfilzomib—PSMB9—S Phase—CCND1—pharynx cancer	0.00322	0.00788	CbGpPWpGaD
Carfilzomib—ABCB1—trachea—pharynx cancer	0.00307	0.00519	CbGeAlD
Carfilzomib—PSMB1—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.00303	0.00741	CbGpPWpGaD
Carfilzomib—PSMB5—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.00303	0.00741	CbGpPWpGaD
Carfilzomib—PSMB2—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.00303	0.00741	CbGpPWpGaD
Carfilzomib—PSMB10—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.003	0.00735	CbGpPWpGaD
Carfilzomib—PSMB9—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00299	0.00731	CbGpPWpGaD
Carfilzomib—PSMB8—p53-Dependent G1 DNA Damage Response—TP53—pharynx cancer	0.00299	0.00731	CbGpPWpGaD
Carfilzomib—PSMB1—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00291	0.00711	CbGpPWpGaD
Carfilzomib—PSMB5—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00291	0.00711	CbGpPWpGaD
Carfilzomib—PSMB2—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00291	0.00711	CbGpPWpGaD
Carfilzomib—PSMB8—G1/S DNA Damage Checkpoints—TP53—pharynx cancer	0.00287	0.00701	CbGpPWpGaD
Carfilzomib—PSMB5—Apoptosis—CDH1—pharynx cancer	0.00273	0.00669	CbGpPWpGaD
Carfilzomib—PSMB1—Apoptosis—CDH1—pharynx cancer	0.00273	0.00669	CbGpPWpGaD
Carfilzomib—PSMB2—Apoptosis—CDH1—pharynx cancer	0.00273	0.00669	CbGpPWpGaD
Carfilzomib—PSMB8—Apoptosis—CDH1—pharynx cancer	0.0027	0.00659	CbGpPWpGaD
Carfilzomib—ABCB1—lymphoid tissue—pharynx cancer	0.00267	0.00452	CbGeAlD
Carfilzomib—PSMB10—Metabolism—CNDP2—pharynx cancer	0.00245	0.006	CbGpPWpGaD
Carfilzomib—PSMB1—S Phase—CCND1—pharynx cancer	0.00245	0.006	CbGpPWpGaD
Carfilzomib—PSMB5—S Phase—CCND1—pharynx cancer	0.00245	0.006	CbGpPWpGaD
Carfilzomib—PSMB2—S Phase—CCND1—pharynx cancer	0.00245	0.006	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—CNDP2—pharynx cancer	0.00244	0.00597	CbGpPWpGaD
Carfilzomib—ABCB1—spinal cord—pharynx cancer	0.00242	0.00409	CbGeAlD
Carfilzomib—PSMB8—S Phase—CCND1—pharynx cancer	0.00242	0.00591	CbGpPWpGaD
Carfilzomib—PSMB5—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00228	0.00557	CbGpPWpGaD
Carfilzomib—PSMB1—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00228	0.00557	CbGpPWpGaD
Carfilzomib—PSMB2—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00228	0.00557	CbGpPWpGaD
Carfilzomib—PSMB8—Mitotic G1-G1/S phases—CCND1—pharynx cancer	0.00224	0.00549	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—B4GALT5—pharynx cancer	0.00222	0.00543	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—ADH7—pharynx cancer	0.00222	0.00543	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle Checkpoints—TP53—pharynx cancer	0.00222	0.00543	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—B4GALT5—pharynx cancer	0.00221	0.00541	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—ADH7—pharynx cancer	0.00221	0.0054	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle Checkpoints—TP53—pharynx cancer	0.00221	0.0054	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CD79A—pharynx cancer	0.00217	0.00531	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CD79A—pharynx cancer	0.00216	0.00529	CbGpPWpGaD
Carfilzomib—ABCB1—head—pharynx cancer	0.00215	0.00364	CbGeAlD
Carfilzomib—PSMB10—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.00199	0.00486	CbGpPWpGaD
Carfilzomib—PSMB9—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.00198	0.00484	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—ADH1B—pharynx cancer	0.00195	0.00476	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—ADH1B—pharynx cancer	0.00194	0.00474	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—B4GALT5—pharynx cancer	0.00186	0.00455	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—CNDP2—pharynx cancer	0.00186	0.00455	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—CNDP2—pharynx cancer	0.00186	0.00455	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—CNDP2—pharynx cancer	0.00186	0.00455	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—B4GALT5—pharynx cancer	0.00185	0.00453	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—CNDP2—pharynx cancer	0.00183	0.00448	CbGpPWpGaD
Carfilzomib—PSMB10—Apoptosis—TP53—pharynx cancer	0.00177	0.00433	CbGpPWpGaD
Carfilzomib—PSMB9—Apoptosis—TP53—pharynx cancer	0.00176	0.00431	CbGpPWpGaD
Carfilzomib—PSMB10—B Cell Activation—EGFR—pharynx cancer	0.00176	0.00429	CbGpPWpGaD
Carfilzomib—PSMB9—B Cell Activation—EGFR—pharynx cancer	0.00175	0.00427	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—B4GALT5—pharynx cancer	0.00168	0.00412	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—B4GALT5—pharynx cancer	0.00168	0.00412	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—B4GALT5—pharynx cancer	0.00168	0.00412	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ADH7—pharynx cancer	0.00168	0.00411	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ADH7—pharynx cancer	0.00168	0.00411	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ADH7—pharynx cancer	0.00168	0.00411	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle Checkpoints—TP53—pharynx cancer	0.00168	0.00411	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle Checkpoints—TP53—pharynx cancer	0.00168	0.00411	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle Checkpoints—TP53—pharynx cancer	0.00168	0.00411	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—B4GALT5—pharynx cancer	0.00166	0.00406	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ADH7—pharynx cancer	0.00166	0.00406	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle Checkpoints—TP53—pharynx cancer	0.00166	0.00405	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD79A—pharynx cancer	0.00165	0.00403	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD79A—pharynx cancer	0.00165	0.00403	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD79A—pharynx cancer	0.00165	0.00403	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD79A—pharynx cancer	0.00162	0.00397	CbGpPWpGaD
Carfilzomib—ABCB1—lymph node—pharynx cancer	0.00151	0.00255	CbGeAlD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.00151	0.00368	CbGpPWpGaD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.00151	0.00368	CbGpPWpGaD
Carfilzomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.00151	0.00368	CbGpPWpGaD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.00149	0.00363	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ADH1B—pharynx cancer	0.00147	0.00361	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ADH1B—pharynx cancer	0.00147	0.00361	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ADH1B—pharynx cancer	0.00147	0.00361	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ADH1B—pharynx cancer	0.00145	0.00356	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—B4GALT5—pharynx cancer	0.00141	0.00345	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—B4GALT5—pharynx cancer	0.00141	0.00345	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—B4GALT5—pharynx cancer	0.00141	0.00345	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—B4GALT5—pharynx cancer	0.00139	0.0034	CbGpPWpGaD
Carfilzomib—PSMB5—Apoptosis—TP53—pharynx cancer	0.00134	0.00328	CbGpPWpGaD
Carfilzomib—PSMB1—Apoptosis—TP53—pharynx cancer	0.00134	0.00328	CbGpPWpGaD
Carfilzomib—PSMB2—Apoptosis—TP53—pharynx cancer	0.00134	0.00328	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—EGFR—pharynx cancer	0.00133	0.00325	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—EGFR—pharynx cancer	0.00133	0.00325	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—EGFR—pharynx cancer	0.00133	0.00325	CbGpPWpGaD
Carfilzomib—PSMB8—Apoptosis—TP53—pharynx cancer	0.00132	0.00324	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD79A—pharynx cancer	0.00132	0.00322	CbGpPWpGaD
Carfilzomib—PSMB8—B Cell Activation—EGFR—pharynx cancer	0.00131	0.00321	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD79A—pharynx cancer	0.00131	0.00321	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CDH1—pharynx cancer	0.00121	0.00296	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CDH1—pharynx cancer	0.0012	0.00295	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.0011	0.00269	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.0011	0.00268	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD79A—pharynx cancer	0.000999	0.00244	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD79A—pharynx cancer	0.000999	0.00244	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD79A—pharynx cancer	0.000999	0.00244	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—CCND1—pharynx cancer	0.000985	0.00241	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD79A—pharynx cancer	0.000985	0.00241	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—CCND1—pharynx cancer	0.00098	0.0024	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CDH1—pharynx cancer	0.000917	0.00224	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CDH1—pharynx cancer	0.000917	0.00224	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CDH1—pharynx cancer	0.000917	0.00224	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CDH1—pharynx cancer	0.000904	0.00221	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000835	0.00204	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000835	0.00204	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000835	0.00204	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000823	0.00201	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—CCND1—pharynx cancer	0.000746	0.00183	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—CCND1—pharynx cancer	0.000746	0.00183	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—CCND1—pharynx cancer	0.000746	0.00183	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—CCND1—pharynx cancer	0.000736	0.0018	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CDH1—pharynx cancer	0.000734	0.0018	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CDH1—pharynx cancer	0.000731	0.00179	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—EGFR—pharynx cancer	0.000708	0.00173	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—EGFR—pharynx cancer	0.000704	0.00172	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TP53—pharynx cancer	0.000649	0.00159	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TP53—pharynx cancer	0.000646	0.00158	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CDH1—pharynx cancer	0.000556	0.00136	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CDH1—pharynx cancer	0.000556	0.00136	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CDH1—pharynx cancer	0.000556	0.00136	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CDH1—pharynx cancer	0.000549	0.00134	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CNDP2—pharynx cancer	0.000547	0.00134	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—EGFR—pharynx cancer	0.000536	0.00131	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—EGFR—pharynx cancer	0.000536	0.00131	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—EGFR—pharynx cancer	0.000536	0.00131	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—EGFR—pharynx cancer	0.000529	0.00129	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000507	0.00124	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ADH7—pharynx cancer	0.000495	0.00121	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—pharynx cancer	0.000492	0.0012	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—pharynx cancer	0.000492	0.0012	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—pharynx cancer	0.000492	0.0012	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—pharynx cancer	0.000485	0.00119	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ADH1B—pharynx cancer	0.000434	0.00106	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—EGFR—pharynx cancer	0.000429	0.00105	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—EGFR—pharynx cancer	0.000427	0.00105	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—B4GALT5—pharynx cancer	0.000415	0.00101	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000398	0.000973	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EGFR—pharynx cancer	0.000396	0.000969	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EGFR—pharynx cancer	0.000394	0.000965	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCND1—pharynx cancer	0.000354	0.000865	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCND1—pharynx cancer	0.000352	0.000861	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000334	0.000817	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—pharynx cancer	0.000325	0.000796	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—pharynx cancer	0.000325	0.000796	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—pharynx cancer	0.000325	0.000796	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—pharynx cancer	0.000321	0.000785	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—pharynx cancer	0.0003	0.000735	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—pharynx cancer	0.0003	0.000735	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—pharynx cancer	0.0003	0.000735	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—pharynx cancer	0.000296	0.000724	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—pharynx cancer	0.000278	0.000679	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—pharynx cancer	0.000276	0.000676	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—pharynx cancer	0.000268	0.000656	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—pharynx cancer	0.000268	0.000656	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—pharynx cancer	0.000268	0.000656	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—pharynx cancer	0.000264	0.000647	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—pharynx cancer	0.000233	0.00057	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—pharynx cancer	0.000232	0.000567	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—pharynx cancer	0.00021	0.000515	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—pharynx cancer	0.00021	0.000515	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—pharynx cancer	0.00021	0.000515	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—pharynx cancer	0.000207	0.000507	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—pharynx cancer	0.000177	0.000432	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—pharynx cancer	0.000177	0.000432	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—pharynx cancer	0.000177	0.000432	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—pharynx cancer	0.000174	0.000426	CbGpPWpGaD
